NasdaqGS:DYNBiotechs
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
Dyne Therapeutics plans to submit an accelerated application for its Duchenne muscular dystrophy drug, targeting a potential commercial launch in early 2027.
The company has completed enrollment in its Phase 1/2 trial in myotonic dystrophy type 1 and started a Phase 3 trial for DYNE-101 in DM1.
New long term DELIVER trial data report meaningful improvements in lung and cardiac function in patients with Duchenne muscular dystrophy.
For investors watching NasdaqGS:DYN, these clinical and...